Eaton Vance Worldwide Health Sciences does not have any notable advantages over its rivals, and the strategy retains its Average People and Process ratings.
Eaton Vance Worldwide Health Sciences Fund Class A ETHSX
- NAV / 1-Day Return 13.23 / 0.00
- Total Assets 779.0M
-
Adj. Expense Ratio
1.180%
- Expense Ratio 1.170%
- Distribution Fee Level Below Average
- Share Class Type Front Load
- Category Health
- Investment Style Large Value
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.51%
- Turnover 30%
USD | NAV as of Oct 02, 2026 | 1-Day Return as of Oct 02, 2026, 10:53 PM GMT+0
Morningstar’s Analysis ETHSX
Will ETHSX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 59.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 12.37 | 97M | Healthcare |
AbbVie Inc | 7.20 | 56M | Healthcare |
Johnson & Johnson | 7.10 | 56M | Healthcare |
UnitedHealth Group Inc | 5.79 | 45M | Healthcare |
AstraZeneca PLC | 5.54 | 43M | Healthcare |
Roche Holding AG | 5.47 | 43M | — |
Merck & Co Inc | 5.39 | 42M | Healthcare |
Bristol-Myers Squibb Co | 4.28 | 34M | Healthcare |
Vertex Pharmaceuticals Inc | 3.45 | 27M | Healthcare |
Gilead Sciences Inc | 3.10 | 24M | Healthcare |
United States